- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2016
- Public Summary Document (PSD) November 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2016 PBAC Meeting - Word
Pembrolizumab (additional strength) – November 2016
Pembrolizumab (additional strength): Solution for infusion 100 mg; Keytruda®
Last updated
29 May 2017